In plain terms

The claim being assessed: Microplastic exposure at real-world human levels causally increases major adverse cardiovascular events.

Where the evidence stands: Γ — Plausible mechanism. There is a believable biological story and partial support, but the causal step has not been demonstrated.

What this mechanism does: The evidence reviewed does not show this mechanism causing the outcome. That does not show it has no effect.

Strongest evidence for it: The preregistered primary-subclaim rule returns Γ from the human particle-event SC2. Fifty-nine original reports include analytical studies, experimental injury, human observational outcomes and distinct PFAS kinetics/removal. Experimental plausibility and prospective association do not yet establish the exposure-specific human cardiovascular dependency. Genuine detection and genuine PFAS burden reduction are retained without converting them to demonstrated clinical harm or detox benefit.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Leading among models compared

What this review means

Particles are detected in cardiovascular samples and associate with events; their causal contribution at real-world human exposure and the clinical benefit of detox remain unresolved.

Implications for health and treatment: The preregistered primary-subclaim rule returns Γ from the human particle-event SC2. Fifty-nine original reports include analytical studies, experimental injury, human observational outcomes and distinct PFAS kinetics/removal. Experimental plausibility and prospective association do not yet establish the exposure-specific human cardiovascular dependency. Genuine detection and genuine PFAS burden reduction are retained without converting them to demonstrated clinical harm or detox benefit.

Limits for individual care: 59 primary reports with 2 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 59 primary reports; claims: 66; verified: 66; unverified: 0. Verification is bounded attribution. Access: 2 partial-body and 57 bounded abstract/status examinations. Literature cutoff: 2026-10-13; source examination UTC date: 2026-10-13. No complete-paper audit or blinded calibration claimed. Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 3 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Particles are detected in cardiovascular samples and associate with events; their causal contribution at real-world human exposure and the clinical benefit of detox remain unresolved.

Deciding experiment: A prospective natural exposure-mitigation study compares baseline-defined communities affected by a specific verified source with matched independent control communities. Register polymer/particle sizes, chemical coexposures, repeated internal-dose assays, clean procedural blanks, baseline vascular risk and adjudicated myocardial infarction/stroke/cardiovascular-death endpoints. Separately randomize a lawful safe chemical-burden-lowering strategy in appropriately eligible PFAS-exposed adults to prespecified clinical function/health and harm outcomes; do not equate serum decline with success.

Belief versus evidence: The preregistered primary-subclaim rule returns Γ from the human particle-event SC2. Fifty-nine original reports include analytical studies, experimental injury, human observational outcomes and distinct PFAS kinetics/removal. Experimental plausibility and prospective association do not yet establish the exposure-specific human cardiovascular dependency. Genuine detection and genuine PFAS burden reduction are retained without converting them to demonstrated clinical harm or detox benefit.

Best-supported rival: Disease-related trapping and barrier disruption — the highest-ranked model that is not the nominal hypothesis. Marfella PMID 38446676 is the strongest human clinical association but cannot distinguish causal injury from disease-related trapping. PMID 39366047 directly shows a barrier-damage association without particle-cytokine association, while PMID 39841831 demonstrates experimental obstruction. A validated natural exposure-reduction study with repeated internal sampling would separate the leading models.

COMPETING MECHANISTIC MODELS

Rank 1: Particles contribute to vascular injury (Γ). Particles directly damage or obstruct vasculature and amplify disease through inflammatory or biophysical pathways. Prospective plaque/event associations and experimental injury, leakiness, clotting and obstruction make contribution plausible. Human ordinary-dose clinical necessity/sufficiency and exposure calibration remain unestablished.

Rank 2: Disease-related trapping and barrier disruption (Γ). Pre-existing disease or procedures alter uptake, retention or measured burden, making particles partly downstream markers. Barrier-damage CSF findings, surgical pre/post measurements and different diseased/healthy tissue comparisons provide directionally relevant support. They do not show all particle-event associations are explained by trapping; prospective event association remains concerning.

Rank 3: Chemical and coexposure toxicity (Γ). Adsorbed metals, additives or distinct PFAS chemicals contribute injury attributed to the particle label. Polystyrene-plus-lead/cadmium/PFAS-analogue experiments show coexposure-dependent injury; chemical epidemiology uses a different exposure entity. Combined exposures and cell pharmacology do not quantify each contribution to human clinical events or eliminate pure-particle effects.

Rank 4: Measurement and procedural-source heterogeneity (Β). Assay thresholds and clinical/laboratory materials explain part of measured tissue/blood differences. Contamination-aware studies identify procedural material signatures and nonplastic suspects, while pyrolysis and imaging quantify different properties. Orthogonal chemical/microscopic findings make a universal all-artifact explanation untenable; heterogeneity is not proof of no exposure.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Microplastic exposure at real-world human levels causally increases major adverse cardiovascular events.

The declared clinical causal proposition is represented by SC2. Target engagement, superiority, mechanism, generalization and benefit-harm companions are separately reported and do not substitute for this primary claim.

Selection: position 10 in the registered editorial traffic-priority list; registration timestamp 2026-10-13T15:39:25.266647+00:00. Ranked topics are editorial priorities, not measured worldwide popularity or a preassigned verdict. Registered claim assessed against original sources; no independent blinded calibration is claimed.

Evidence and causal interpretation

Rubric fit: No environmental-cardiovascular toxicology rubric ships in the frozen framework. Rubric 06 is explicitly adapted to a specified exposure changing a hard cardiovascular clinical phenotype, not organismal lifespan. Rubric 05 governs particle-specific inflammatory mediation. Detection is an analytical/descriptive finding whose existence is separated from clinical causality. Original caps, ladder and literal quoted rubric thresholds remain unchanged; PFAS chemical removal is not particle removal.

Detection is a real analytical question and causation is another. Blood, cardiac-surgery tissue, plaques and thrombi have yielded chemically identified polymers, with some microscopic corroboration. Pyrolysis reports polymer mass while spectroscopy and microscopy report different particle properties. These measurements cannot be interchanged without validation. Procedure-linked exposure and contamination-aware workflows also show why a specimen’s original exposure source must be examined.

The pivotal human event report follows patients already undergoing carotid surgery. Selected original Methods and Results confirm observational grouping after plaque analysis, blinded clinical event adjudication, exclusions for perioperative complications or missing/lost follow-up and a composite of nonfatal infarction, nonfatal stroke or all-cause death. The adjusted hazard ratio is a prognostic association, not a causal multiplier. Post-MI PVC results add another selected clinical context but contain ambiguous indexed odds/fold wording, so no numerical causal-risk conversion is used.

Experimental injury is substantial enough to support plausibility, but exposure matters. Administered particles can promote lesions, fibrosis, dysfunction, endothelial leakiness or microvascular obstruction. Male/female contrasts, low-dose histologic nulls, surface-dependent clotting and baseline induced injury show boundaries. Inhibitor and knockdown results narrow selected experimental routes; cell-only rescue, broad redox suppression and adsorbed-metal coexposures do not establish a specific ordinary-dose human inflammatory mediator.

PFAS is a chemical family, not another name for microplastic particles. The examined chemical clinical-event literature uses prospective coronary-disease comparisons, geographic contamination and occupational exposure estimates. It includes uncertainties and noncardiovascular outcomes; lipid associations and child cardiovascular morphology cannot establish broad adult major-event causation. PIVUS repeated sampling identifies chemical-specific water/exposure kinetics, not clinical benefit from detox.

Burden reduction is genuinely demonstrated for selected PFAS. The randomized firefighter trial lowers serum chemicals, with distinct within-group and between-group contrasts. Selected Results show no significant improvement in several laboratory-health panels, lower hemoglobin after blood donation and more adverse events after plasma donation. Resin crossover studies also lower serum PFAS but assess concentration as the primary endpoint. No examined trial demonstrates that established human particle removal prevents cardiovascular events, or that a retail detox product reproduces the tested chemical interventions and improves health.

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. The preregistered primary-subclaim rule returns Γ from the human particle-event SC2. Fifty-nine original reports include analytical studies, experimental injury, human observational outcomes and distinct PFAS kinetics/removal. Experimental plausibility and prospective association do not yet establish the exposure-specific human cardiovascular dependency. Genuine detection and genuine PFAS burden reduction are retained without converting them to demonstrated clinical harm or detox benefit. Sensitivities: weakest-link Α; primary-subclaim Γ; scope-matched Γ.

Decisive-perturbation inventory and causal tally

[1] Prospective carotid-surgery cohort follows 257 of 304 enrolled for about 34 months; plaque polymers associate with a composite of myocardial infarction, stroke or all-cause death. The reported 4.53 hazard ratio is observational and the composite includes all-cause death; diseased-plaque selection, residual confounding and contamination do not isolate particle causation.

[19] Prospective post-MI cohort follows 110 of 142 patients for about 31.5 months; coronary PVC concentration associates with MACE and inflammatory markers, with an additional 21-patient thrombus sample. Observational odds estimates are not randomized risks; the abstract's fold-increase wording differs from its listed OR, so numeric causal-risk conversion is withheld.

[24] Mouse in-vivo imaging connects circulating particle-phagocyte aggregates with cortical microvascular obstruction, reduced flow and neurobehavioral abnormalities. Administered bloodstream exposure and species-specific capillary conditions do not quantify typical human oral exposure or clinical stroke incidence.

[27] Daily 10 mg/kg gavage for nine weeks increased aortic-root lesions in lean male LDLR-deficient mice but not females, without lipid or adiposity change. The sex boundary and sensitized genotype are experimental; the brachiocephalic estimate was nonsignificant, and asserted environmental relevance is not validated human dose equivalence.

[40] Six-week oral polystyrene caused mouse apoptosis, fibrosis and dysfunction and worsened isoprenaline injury; HIPK2 inhibition reduced selected cardiotoxicity. Mouse dose and pathological-state manipulation do not establish human environmental internal exposure or major-event causation.

[45] Twenty-eight CSF samples associated some polymers with barrier-damage markers but did not associate particle concentrations with IL6 or IL8. Infection-related barrier injury provides a reverse-direction alternative; small cross-sectional CSF data do not disprove all vascular inflammation mechanisms.

[53] Randomized-sequence open-label crossover in 45 highly exposed adults reduced serum PFOS by about 60% with anion-exchange resin versus observation. Primary endpoint was serum concentration, not clinical benefit; absence of serious events in a small short study is not proof of broad safety or efficacy of detox products.

[54] Randomized 285-firefighter trial reduced selected serum PFAS; body Results distinguish within-group from between-group chemical contrasts and report no improvement in several laboratory-health panels. Burden reduction is not clinical-event efficacy or demonstrated particle clearance; blood donation lowered hemoglobin and plasma donation had more adverse events. Donor eligibility and sex distribution restrict scope.

Tally: 0 positive qualifying study units across scoped subclaims; 31 screened discriminating contrast units. These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. No positive qualifying real-world human SC2 causal study unit was examined. Animal positive experimental injury is not independently calibrated human exposure; simulations, cytokines and dose assertions alone earn no clinical causal credit. PFAS chemical burden-removal successes do not count as particle removal or clinical health crossings.

No positive field-valid crossing was verified for the registered causal scope in this bounded audit. Pivotal null or negative tests remain informative; their implications depend on comparator quality, target engagement, power and the registered scope.

Cap audit, precedence and Β/Γ/Δ boundary

Animal administrations and cellular mediator interventions can establish effects in their actual experimental systems. They do not establish realistic human major-event dependency without a dose/exposure bridge. Human event associations retain their class limit; complementary causal evidence is not discarded by recapping its weakest component. PFAS serum-removal trials cross kinetics, not clinical health or plastic-particle removal.

Universal six-cap audit: All six universal caps were considered: cell-only inference, unperturbed association, ectopic expression, biomarker-only intervention, forced transfer/seeding, and inherited-to-sporadic scope transfer. Each binds its offered inference; complementary same-scope causal classes are assessed together rather than re-capped in isolation.

Gamma hard-rule audit: All rubric 06 hard rules were reviewed. ROS, mitochondrial, senescence and serum burden changes alone cannot establish clinical events or benefit; one-strain injury does not establish realistic human scope. Clinical events themselves are phenotypes, but measured associations are not controlled perturbations. Rubric 05 marker/cell-only and pleiotropy rules constrain SC3.

SC2 cap: “Mechanistic plausibility plus one-species or in vitro support caps at Γ.” Prospective diseased-cohort associations, pathological samples and experimental animal injury together support plausible contribution. No examined causal human exposure instrument, controlled particle-removal clinical trial or sufficiently validated internal-dose bridge demonstrates the registered real-world human major-event dependency. Marfella uses all-cause death in its composite, not cardiovascular death alone. Animal plaque/cardiac injury remains causal in its experimental setting and cannot substitute for the human event claim.

SC3 cap: “Correlational human data plus in vitro mechanism” Endothelial, macrophage, cardiac and vascular models show multiple plausible particle-sensitive pathways; selected inhibitor or knockdown experiments narrow some experimental routes. Dose, surface chemistry, additive/metal coexposure, susceptible genotype and induced pathology determine these results. No mediator-specific human perturbation establishes particle-specific vascular inflammation as the clinical-event dependency at measured ordinary exposure.

SC5 cap: “Pure association evidence — however large, however replicated — cannot exceed Β.” Chemical-specific clinical-event evidence is observational: prospective coronary-disease case-control associations, residence-defined mortality and occupational estimates with differing confounding structures. Surrogate lipids and developmental imaging are not major events. In the examined corpus, no independent causal human instrument establishes the broad PFAS major-event claim. This does not adjudicate every PFAS compound, cancer, hepatic or developmental endpoint.

SC6 cap: “Biomarker change without functional/phenotypic change caps at Γ.” Randomized donation and randomized-sequence resin studies demonstrate lower serum concentrations of selected PFAS, with chemical-specific differential effects. This provides a genuine physiological intervention result but not clinical health improvement. The donation body reports no significant between-group improvement in several clinical laboratory panels, reduced hemoglobin after blood donation and more adverse events after plasma donation. Burden reduction alone retains the biomarker-to-health Γ ceiling.

SC1 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Chemically identified polymers and selected microscopic corroboration support a real human internal-exposure finding in blood, cardiovascular tissue and surgical samples. However, detection does not identify the original exposure route, and some procedural or laboratory sources are directly documented. The causal exposure-to-tissue proposition remains partial-system support. This letter is not a rating of whether the particles exist or a claim that all detection is artifact.

SC2 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Prospective diseased-cohort associations, pathological samples and experimental animal injury together support plausible contribution. No examined causal human exposure instrument, controlled particle-removal clinical trial or sufficiently validated internal-dose bridge demonstrates the registered real-world human major-event dependency. Marfella uses all-cause death in its composite, not cardiovascular death alone. Animal plaque/cardiac injury remains causal in its experimental setting and cannot substitute for the human event claim.

SC3 field-valid definition: “ - Cell-type-specific conditional knockout or depletion - Pathway-specific blockade (not broad immunosuppression) changing disease course - Human targeted therapy with mechanistic alignment showing disease-modifying effect” Positive full-scope result: no. Endothelial, macrophage, cardiac and vascular models show multiple plausible particle-sensitive pathways; selected inhibitor or knockdown experiments narrow some experimental routes. Dose, surface chemistry, additive/metal coexposure, susceptible genotype and induced pathology determine these results. No mediator-specific human perturbation establishes particle-specific vascular inflammation as the clinical-event dependency at measured ordinary exposure.

SC4 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. The examined human reduction trials manipulate soluble PFAS chemicals and report chemical-burden endpoints; they do not measure solid-particle clearance or establish cardiovascular benefit of removing particles. Observational particle cohorts do not test removal. The particle-removal clinical benefit remains Α within this bounded source set, not a proven negative or a claim that no future removal method could work.

SC5 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Chemical-specific clinical-event evidence is observational: prospective coronary-disease case-control associations, residence-defined mortality and occupational estimates with differing confounding structures. Surrogate lipids and developmental imaging are not major events. In the examined corpus, no independent causal human instrument establishes the broad PFAS major-event claim. This does not adjudicate every PFAS compound, cancer, hepatic or developmental endpoint.

SC6 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Randomized donation and randomized-sequence resin studies demonstrate lower serum concentrations of selected PFAS, with chemical-specific differential effects. This provides a genuine physiological intervention result but not clinical health improvement. The donation body reports no significant between-group improvement in several clinical laboratory panels, reduced hemoglobin after blood donation and more adverse events after plasma donation. Burden reduction alone retains the biomarker-to-health Γ ceiling.

SC1 applied rubric adaptation (distinct from the unchanged literal criterion): Assess contamination-controlled chemical identity, microscopic corroboration, procedural sources and exposure provenance; confirmed detection is descriptive and does not itself earn clinical causal crossing.

SC2 applied rubric adaptation (distinct from the unchanged literal criterion): A field-valid equivalent may be a strong natural exposure experiment, valid causal instrument or controlled mitigation/removal with hard clinical outcomes and measured internal doses; an unethical deliberate human exposure RCT is not required.

SC3 applied rubric adaptation (distinct from the unchanged literal criterion): Apply pathway- or cell-type-resolved in-vivo perturbation to clinical vascular injury at matched realistic exposure, with particle versus additive/chemical controls.

SC4 applied rubric adaptation (distinct from the unchanged literal criterion): Require verified established particle burden and controlled intervention-sensitive clinical benefit-harm; chemical serum reduction is not a particle result.

SC5 applied rubric adaptation (distinct from the unchanged literal criterion): Require compound-specific pre-outcome exposure and independent causal clinical instruments; geographic/occupational associations and risk-factor surrogates cannot by themselves prove broad event causality.

SC6 applied rubric adaptation (distinct from the unchanged literal criterion): Count serum reduction as demonstrated kinetics, but require clinical benefit-harm endpoints for the registered health proposition.

SC1 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Ex vivo functional assays alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Cytokine profile plus in vitro mechanistic work, no in vivo necessity” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Broad immunosuppression effect with pleiotropy” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Correlational human data plus in vitro mechanism” Triggered literally for this assembled scoped case; it is the rubric cap recorded for SC3 in the cap audit above. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC6 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC6 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC6 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC6 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC6 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC6 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

Upward threshold ladder

SC1 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Validate exposure-to-tissue provenance using repeated chemically corroborated sampling with procedural blanks and source-specific exposure changes; keep analytical detection separate from disease causation.

SC2 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Establish a replicated prospective population exposure contrast or valid natural mitigation experiment with internal-dose validation, adjudicated clinical endpoints and independent confounder control.

SC3 Δ: “Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.” Satisfied: no. Manipulate a specified mediator at realistic measured internal exposures, distinguish particles from additives and show altered vascular disease endpoints with rescue/specificity controls.

SC4 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Demonstrate controlled particle-specific burden reduction followed by fewer adjudicated clinical events or better validated function, with harms measured.

SC5 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Obtain compound-specific causal exposure instruments or natural mitigation contrasts tied to clinical events, with independent biomonitoring and confounding checks.

SC6 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Test burden-lowering strategies against prespecified clinical health/function endpoints and adverse events; concentration change alone cannot cross the health threshold.

Upper ladder: Natural contamination mitigation, independent exposure instruments and controlled safe burden reduction can make upper rungs reachable without intentionally exposing humans to suspected harm. The examined particle cohorts and PFAS ecological/occupational contrasts do not yet provide a validated hard-event causal exposure instrument. Burden-lowering trials lack clinical benefit endpoints; animal administrations lack a calibrated ordinary human dose bridge.

Independence: All grades remain below Ζ. Distinct exposure assays, cohorts and species do not automatically exclude shared exposure misclassification, disease selection or dose-translation failures. ApoE high-fat 19-week platform reports are conservatively grouped; PIVUS and its repeated analyses share participants. Experimental and observational lines inform plausibility without claiming completed human causal convergence.

Falsification and pitfalls

Inflammation-first mechanism is not universal across measured exposure contexts. CSF particle concentrations did not correlate with measured inflammatory cytokines despite barrier associations; anionic leakiness has noncytotoxic biophysical support. Additional downgrade: False.

Burden-lowering does not establish health improvement. Donation lowers PFAS but selected clinical laboratory panels do not improve significantly; no clinical event efficacy was assessed. Additional downgrade: False.

Mistaking presence for primacy. Polymer detection in plaque or thrombi does not establish the cause of pre-existing vascular disease.

Association dressed as mechanism. Adjusted hazard/odds estimates and statistical lipid mediation are not isolated causal perturbations.

Selective generalization. High-dose, susceptible-genotype and induced-disease models cannot define ordinary human exposure without calibration.

Confirmation by biomarker. Serum PFAS reduction, ROS and pathway readouts are not clinical health benefit.

Mechanism conflation. Plastic particles, adsorbed metals, additives and PFAS chemicals require distinct attribution.

Scope fitted to outcome. Surgical/diseased cohorts and experimental sex/genotype boundaries are explicit; no post-outcome susceptible subgroup rescues full scope.

Adversarial steelman: above, then below

Δ could be defended from a prospective human event cohort combined with animal atherosclerosis, vascular obstruction and cardiac-function perturbations. The strongest version would require validated dose translation or a natural human exposure instrument that excludes disease-related retention and coexposure explanations.

Β could be defended from the observational human outcome evidence alone. That would understate directly administered particle injury and experimentally narrowed cellular/vascular routes, while correctly insisting that these do not establish ordinary-exposure human MACE.

Reject Δ for the primary proposition because ordinary-dose human clinical dependency lacks a validated causal bridge; reject Β for the assembled plausibility claim because experimental injury supplies partial-system support. Retain Γ Moderate. PFAS clinical-event SC5 remains Β and does not inherit the particle experiments.

Final score, causal direction and M/S/D

The preregistered primary-subclaim rule returns Γ from the human particle-event SC2. Fifty-nine original reports include analytical studies, experimental injury, human observational outcomes and distinct PFAS kinetics/removal. Experimental plausibility and prospective association do not yet establish the exposure-specific human cardiovascular dependency. Genuine detection and genuine PFAS burden reduction are retained without converting them to demonstrated clinical harm or detox benefit.

For the exact human cardiovascular-event proposition, causal dependency in either direction is not demonstrated by the examined studies, so the framework step 2 label applies. This records unresolved causal attribution, not proof that particles are inert; experimental injury and plausible disease-related retention are stated separately.

Momentum: Mechanistic only. Recent particle injury studies use inhibitor/knockdown, imaging and genotype/sex contrasts, while human event reports remain observational. PFAS donation/resin trials establish kinetics but not the clinical boundary. No verified named pending exact particle-removal event trial was identified.

Stability: Stable. No verified named pending hard-event causal exposure or removal result was identified in this bounded search; a hypothetical natural mitigation study is a proposed experiment, not a pending trigger.

Divergence: Contested. No manufactured belief arithmetic or clinical risk estimate is inferred from provider meters or publication volume. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

A prospective natural exposure-mitigation study compares baseline-defined communities affected by a specific verified source with matched independent control communities. Register polymer/particle sizes, chemical coexposures, repeated internal-dose assays, clean procedural blanks, baseline vascular risk and adjudicated myocardial infarction/stroke/cardiovascular-death endpoints. Separately randomize a lawful safe chemical-burden-lowering strategy in appropriately eligible PFAS-exposed adults to prespecified clinical function/health and harm outcomes; do not equate serum decline with success.

Readout: Repeated chemical/particle-resolved internal burden, clinical cardiovascular events, objective function and adverse effects; distinguish all-cause death from cardiovascular death.. Controls: Independent laboratory and endpoint adjudication, matched baseline risk, source-specific coexposure tracking, repeat sampling, procedural blanks and negative exposure controls; no retrospective susceptible-group selection.. Supporting: A source-linked exposure decrease preceding an independent clinical trajectory change, with mediation/dose calibration and confounder-resistant controls, would support a human causal crossing. Separate clinical benefit after verified PFAS removal would support SC6.. Falsifying: Persistent event risk despite verified meaningful burden reduction or disappearance of associations under validated contamination/coexposure controls would narrow the causal model; a removal biomarker success without health improvement does not establish detox efficacy..

KNOWLEDGE GAPS

Standardized particle-resolved internal dosimetry and procedural contamination controls across human cohorts.

Independent prospective clinical-event cohorts outside pre-existing disease/surgical selection, with cardiovascular death separated from all-cause death.

Validated natural exposure-mitigation contrasts and causal instruments; no unethical deliberate human exposure trial is required.

Realistic dose, polymer/size/surface, sex/genotype and additive controls for mediator-specific vascular experiments.

Controlled human plastic-particle burden removal with clinical benefit-harm endpoints, distinct from chemical serum kinetics.

Compound-specific PFAS clinical-event attribution and controlled removal-health outcomes, rather than extrapolation from lipids or blood concentration.

REVIEWER NOTES

59 original reports were examined across the coordinator and delegated appraiser using original abstracts/status records. Selected Methods/Results from two original papers were read and receipted at draft completion. These records include analytical validation, experimental toxicology, observational clinical outcomes and distinct PFAS interventions; they are not 59 human causal studies. Most full papers/supplements were not audited. An accidentally retrieved unselected sports paper earns no examination credit. Retracted source 35731224 was excluded. Consensus supplements aspect reconciliation and does not supply primary-count credit. No independent blinded scientific review is claimed. Observed Consensus Pro browser synthesis was reconciled in eight source-aspect comparisons. Provider meter, paper-count grid and review citations were not converted to examined-primary or independent-cohort counts. Categorical unmeasured particle nonremoval was softened to lack of demonstrated particle clearance.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

Consensus and original-source reconciliation

Consensus describes 304 carotid-surgery participants and 257 completing follow-up. The examined original body records 312 screened, eight perioperative stroke/death exclusions and 47 with incomplete data or lost follow-up, leaving 257. Its primary endpoint includes nonfatal infarction, nonfatal stroke or ALL-CAUSE death, not cardiovascular death alone. Events were adjudicated without knowledge of polymer results, but exposure groups were observational and visits were unscheduled. Original PMID38446676.

The provider reproduces adjusted HR 4.53 and acknowledges absent causality. Selected original Results confirm 30/150 versus 8/107 events and an adjusted HR 4.53; Methods and Discussion retain residual socioeconomic, air-pollution and dietary confounding and possible contamination. The provider coverage grid lists seven longitudinal carotid MACE papers, but cited reviews or repeated citations do not create seven primary independent cohorts. We retain one parent study unit and do not use its meter or coverage counts as causal probabilities. Original PMID38446676.

Consensus reports 110 patients with 31.5-month follow-up and OR 1.090 for PVC/event association. The original abstract confirms these observations in a 142-enrolled prospective observational cohort plus a separate 21-patient thrombus series. The listed OR 2.374 and accompanying 1.374-fold-increase wording require interpretation not resolved by our abstract access; no uncertain numerical risk conversion is reproduced. These odds associations do not establish particle-caused clinical events. Original PMID40007360.

The provider gives 285 firefighters, 52 weeks and plasma-related PFOS/PFHxS reduction. Selected original Methods/Results independently confirm randomization, donor eligibility and chemical serum endpoints. Blood PFHxS change is nonsignificant within group but significantly lower than observation between groups because the control trajectory differs. Neither contrast is evidence of human plastic-particle clearance; the trial did not measure a particle-removal endpoint. Original PMID35394514.

Consensus correctly says no cardiovascular-event reduction was demonstrated. The original trial was powered for concentration changes; selected Results find no significant between-group improvement in lipid, thyroid, liver or kidney panels, lower hemoglobin after blood donation and more adverse events with plasma donation. The provider categorical statement that these procedures do not extract solid particles goes beyond the tested endpoint. We use the bounded conclusion that these trials do not establish particle clearance or clinical-event benefit. Original PMID35394514.

Consensus reports ten exposed participants and a 38% mean PFOS decline during 12-week colesevelam. The examined original abstract confirms chemical-specific serum/fecal/urinary measurements, cholestyramine-enhanced fecal PFOS and a small control-period decline. It calls for evaluation of risks, costs and benefits. This is chemical elimination evidence, not a measured plastic-particle endpoint or demonstrated cardiovascular health improvement. Original PMID40974835.

The provider presents low-concentration cardiac-organoid findings as mechanistic support while warning about translation. The original report appraised by the coordinator uses administered polystyrene in mouse/organoid systems with injury/hypertrophy measures. An asserted low internal concentration is not a validated human pharmacokinetic bridge; organoid markers and wall thickness do not supply a prospective human major-event estimate. Original PMID37669592.

The provider distinguishes detection from harm. The examined original blood-method abstract quantifies several polymers in 22 healthy volunteers, with polypropylene below quantification. Chemical mass measurements above thresholds support internal exposure; they do not identify a clinical toxicity threshold, particle-resolved dose or cardiovascular-event dependency. Original PMID35367073.

Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.

Research timeline and gaps: Microplastics and Cardiovascular Disease

Selected publication milestones, not an exhaustive history or discovery priority claim.

2016 — Repeated PIVUS sampling maps compound-specific serum trends; kinetics is distinct from clinical risk. Original PMID27542758.

2017 — Contaminated-water distribution predicts PFHxS trends within the shared PIVUS cohort. Original PMID28780137.

2019 — Prospective PFAS-diabetes results include mostly nonsignificant inverse associations, a boundary against uniform metabolic-harm inference. Original PMID30622063.

2021 — Particle-exposed endothelial/immune models demonstrate activation while leaving human clinical dependency unresolved. Original PMID34788346.

2022 — A contamination-aware pyrolysis workflow detects polymer mass in human blood. Original PMID35367073.

2022 — Randomized donation lowers selected serum PFAS without established clinical health improvement. Original PMID35394514.

2022 — Anionic particles produce biophysical endothelial leakiness, broadening mechanisms beyond inflammatory markers. Original PMID35963861.

2023 — A sensitized high-fat ApoE mouse platform shows administered particle-associated atherosclerosis; dose translation remains open. Original PMID37144527.

2023 — Cardiac-surgery tissue and paired blood analyses highlight clinical procedural sources and diseased-tissue selection. Original PMID37440474.

2024 — A prospective carotid-surgery cohort links plaque polymers to later infarction, stroke or all-cause death, without proving causality. Original PMID38446676.

2024 — Randomized-sequence resin treatment lowers serum PFAS; concentration is its primary outcome. Original PMID38367552.

2024 — Barrier impairment associates with CNS particle burden without a particle-cytokine association. Original PMID39366047.

2025 — A post-MI clinical cohort adds coronary PVC/event association, with ambiguous indexed numerical wording retained as a limitation. Original PMID40007360.

2025 — Mouse imaging demonstrates particle-phagocyte obstruction and reduced microvascular flow under administered exposure. Original PMID39841831.

2025 — Prospective PFAS/lipidomics case-control work links chemicals with post-PCI events, while causal mediation remains unisolated. Original PMID40571603.

2025 — Lean LDLR-deficient mice show a male-versus-female atherosclerosis boundary under daily gavage. Original PMID41275764.

2025 — Small crossover interventions distinguish enhanced chemical excretion from serum concentration and clinical benefit. Original PMID40974835.

Research gaps

Standardized particle-resolved internal dosimetry and procedural contamination controls across human cohorts.

Independent prospective clinical-event cohorts outside pre-existing disease/surgical selection, with cardiovascular death separated from all-cause death.

Validated natural exposure-mitigation contrasts and causal instruments; no unethical deliberate human exposure trial is required.

Realistic dose, polymer/size/surface, sex/genotype and additive controls for mediator-specific vascular experiments.

Controlled human plastic-particle burden removal with clinical benefit-harm endpoints, distinct from chemical serum kinetics.

Compound-specific PFAS clinical-event attribution and controlled removal-health outcomes, rather than extrapolation from lipids or blood concentration.

Boundary experiment

A prospective natural exposure-mitigation study compares baseline-defined communities affected by a specific verified source with matched independent control communities. Register polymer/particle sizes, chemical coexposures, repeated internal-dose assays, clean procedural blanks, baseline vascular risk and adjudicated myocardial infarction/stroke/cardiovascular-death endpoints. Separately randomize a lawful safe chemical-burden-lowering strategy in appropriately eligible PFAS-exposed adults to prespecified clinical function/health and harm outcomes; do not equate serum decline with success.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14.

Scope of checks. All 59 REFERENCES PMIDs verified against PubMed metadata (59/59 resolve to the stated title, first author, journal and year; no retraction or expression-of-concern notice attached to any retained source). Twelve load-bearing claims spot-checked against original abstracts (PMIDs 38446676, 40007360, 39366047, 41275764, 35394514, 38367552, 35367073, 40974835, 37669592, 39841831, 38428296, 37440474). Scoring logic checked against references/hsef-framework.md: hard caps before aggregation, declared primary-subclaim aggregation applied as written, scope-matched and weakest-link sensitivities recomputed, Ζ independence basis, Β/Γ/Δ boundary, confidence-band text, role-of-mechanism derivation order, and the four known upstream builder defects (collective-author dropout, scope-matched misreading, momentum boilerplate, rendering defects).

Rejected findings (checked, no change).

1. Reference years differing by one from the PubMed publication-date year (PMIDs 41352427, 41005896, 36243049, 30622063) — print/issue versus e-pub year; rejected by convention.
2. "257 of 304 enrolled" in item [1] and card [1] — checked against the original abstract, which states 304 enrolled and 257 completing a mean 33.7-month follow-up. The reconciliation section's 312-screened figure is the body's pre-exclusion count and is arithmetically consistent (312 − 8 perioperative exclusions = 304; 304 − 47 incomplete = 257). No change.
3. SC1/SC2/SC4/SC5/SC6 "field-valid definition" blocks quoting lifespan/healthspan criteria — these are the frozen rubric's literal text, and the review separately states the applied adaptation for each subclaim and declares the rubric-fit reasoning. Quoting an ill-fitting literal criterion verbatim while disclosing the adaptation is the framework's documented behaviour, not a misstatement.
4. Role of mechanism epiphenomenon — derivation step 2 ("no demonstrated causal dependency in either direction, only co-occurrence") is correctly applied and correctly not taken from tournament rank.
5. Headline Γ and the primary-subclaim aggregation — SC2 is scope-matched to the registered claim and is Γ; scope-matched and primary-subclaim sensitivities both return Γ. No Ε subclaim is doing the work. No change.
6. Momentum "Mechanistic only" — already the correct value; the artifact text names the study designs rather than a trial programme, consistent with the rule that "Decisive work underway" requires a named artifact.
7. Collective-author rendering defect — no reference in this review has a consortium first author; no instance found.

Residual limitations. Access remains bounded: 2 partial-body and 57 abstract/status examinations, so Methods-level verification of 57 sources was not possible and the corrections above rest on abstracts plus the retained receipts. Item [19]'s odds/fold-increase ambiguity is correctly flagged but not resolvable without the full text. The review's rubric adaptation (an aging rubric applied to an environmental-cardiovascular claim) is disclosed but remains a judgement call that a purpose-built rubric would settle differently.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Marfella R, Prattichizzo F, Sardu C et al. Microplastics and Nanoplastics in Atheromas and Cardiovascular Events. The New England journal of medicine. 2024. PMID 38446676. DOI: 10.1056/NEJMoa2309822. Access: full_text_partial. Study: MARFELLA-CAROTID-2019-2020.

2. Hohenstatt S, Maliandi G, Vollherbst DF et al. Circulating Microplastics in Acute Ischemic Stroke: Feasibility, Variability, and Exploratory Comparisons with Healthy Individuals. Clinical neuroradiology. 2026. PMID 42236542. DOI: 10.1007/s00062-026-01673-1. Access: abstract_metadata. Study: PMID42236542.

3. Sarabia AJ, Martínez B, Martínez MLÁ et al. Isolation and characterization of microplastics from human blood samples by confocal RAMAN microscopy. MethodsX. 2026. PMID 41816352. DOI: 10.1016/j.mex.2026.103841. Access: abstract_metadata. Study: PMID41816352.

4. Wright SL, Gwinnett C, Mudway IS et al. A new screening framework to support the identification of exogenous particles and suspect microplastics in situ in pathological tissue samples. EBioMedicine. 2025. PMID 41187616. DOI: 10.1016/j.ebiom.2025.105984. Access: abstract_metadata. Study: PMID41187616.

5. Macairan JR, Saherwala A, Li F et al. Label-Free Identification and Imaging of Microplastic and Nanoplastic Biouptake Using Optical Photothermal Infrared Microspectroscopy. Environmental science & technology. 2025. PMID 40696889. DOI: 10.1021/acs.est.4c14367. Access: abstract_metadata. Study: PMID40696889.

6. Zhang L, Tian J, Zhu X et al. Cross-platform detection of microplastics in human biological tissues: Comparing spectroscopic and chromatographic approaches. Journal of hazardous materials. 2025. PMID 40179790. DOI: 10.1016/j.jhazmat.2025.138133. Access: abstract_metadata. Study: PMID40179790.

7. Wouters Q, Abakumov S, Van Der Stukken C et al. Hydrogel Transformation Reveals a Conventionally Inaccessible Sub-Micrometer Microplastic Fraction in Intact Human Tissues. ACS nano. 2026. PMID 42689720. DOI: 10.1021/acsnano.6c12376. Access: abstract_metadata. Study: PMID42689720.

8. Sofield CE, Attenborough E, Anderton RS et al. Label-free non-destructive spectroscopic detection of mixed microplastic uptake and differential effects on intestinal epithelial cells. Journal of hazardous materials. 2026. PMID 41616615. DOI: 10.1016/j.jhazmat.2026.141283. Access: abstract_metadata. Study: PMID41616615.

9. Radu ET, Palade NA, Solomon CC et al. Suspected Microplastic-Like Particles Recovered From Paired Human Small Intestine and Large Intestine Specimens: An Exploratory Post-mortem Study. Cureus. 2026. PMID 42807823. DOI: 10.7759/cureus.115390. Access: abstract_metadata. Study: PMID42807823.

10. Wang B, Liang B, Huang Y et al. Long-Chain Acyl Carnitines Aggravate Polystyrene Nanoplastics-Induced Atherosclerosis by Upregulating MARCO. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2023. PMID 37144527. DOI: 10.1002/advs.202205876. Access: abstract_metadata. Study: APOE-HFD-19W-PS-PLATFORM.

11. V L Leonard S, Liddle CR, Atherall CA et al. Microplastics in human blood: Polymer types, concentrations and characterisation using μFTIR. Environment international. 2024. PMID 38761430. DOI: 10.1016/j.envint.2024.108751. Access: abstract_metadata. Study: PMID38761430.

12. Wang K, Du Y, Li P et al. Nanoplastics causes heart aging/myocardial cell senescence through the Ca2+/mtDNA/cGAS-STING signaling cascade. Journal of nanobiotechnology. 2024. PMID 38448951. DOI: 10.1186/s12951-024-02375-x. Access: abstract_metadata. Study: PMID38448951.

13. Yang Y, Xie E, Du Z et al. Detection of Various Microplastics in Patients Undergoing Cardiac Surgery. Environmental science & technology. 2023. PMID 37440474. DOI: 10.1021/acs.est.2c07179. Access: abstract_metadata. Study: PMID37440474.

14. Liu S, Wang C, Yang Y et al. Microplastics in three types of human arteries detected by pyrolysis-gas chromatography/mass spectrometry (Py-GC/MS). Journal of hazardous materials. 2024. PMID 38428296. DOI: 10.1016/j.jhazmat.2024.133855. Access: abstract_metadata. Study: PMID38428296.

15. Zhou Y, Wu Q, Li Y et al. Low-dose of polystyrene microplastics induce cardiotoxicity in mice and human-originated cardiac organoids. Environment international. 2023. PMID 37669592. DOI: 10.1016/j.envint.2023.108171. Access: abstract_metadata. Study: PMID37669592.

16. Wen J, Sun H, Yang B et al. Long-term polystyrene nanoplastic exposure disrupt hepatic lipid metabolism and cause atherosclerosis in ApoE-/- mice. Journal of hazardous materials. 2024. PMID 38306833. DOI: 10.1016/j.jhazmat.2024.133583. Access: abstract_metadata. Study: PMID38306833.

17. Yang Y, Zhang F, Jiang Z et al. Microplastics are associated with elevated atherosclerotic risk and increased vascular complexity in acute coronary syndrome patients. Particle and fibre toxicology. 2024. PMID 39164741. DOI: 10.1186/s12989-024-00596-4. Access: abstract_metadata. Study: PMID39164741.

18. Zhang T, Yang S, Ge Y et al. Unveiling the Heart's Hidden Enemy: Dynamic Insights into Polystyrene Nanoplastic-Induced Cardiotoxicity Based on Cardiac Organoid-on-a-Chip. ACS nano. 2024. PMID 39482939. DOI: 10.1021/acsnano.4c13262. Access: abstract_metadata. Study: PMID39482939.

19. Zhang Y, Gao Q, Gao Q et al. Microplastics and nanoplastics increase major adverse cardiac events in patients with myocardial infarction. Journal of hazardous materials. 2025. PMID 40007360. DOI: 10.1016/j.jhazmat.2025.137624. Access: abstract_metadata. Study: PMID40007360.

20. Wang T, Yi Z, Liu X et al. Multimodal detection and analysis of microplastics in human thrombi from multiple anatomically distinct sites. EBioMedicine. 2024. PMID 38614011. DOI: 10.1016/j.ebiom.2024.105118. Access: abstract_metadata. Study: PMID38614011.

21. Lv J, Tan Z, An Z et al. Co-exposure to polystyrene nanoplastics and F-53B induces vascular endothelial cell pyroptosis through the NF-κB/NLRP3 pathway. Journal of hazardous materials. 2025. PMID 39764954. DOI: 10.1016/j.jhazmat.2025.137114. Access: abstract_metadata. Study: PMID39764954.

22. Ye J, Qiu W, Pang X et al. Polystyrene nanoplastics and cadmium co-exposure aggravated cardiomyocyte damage in mice by regulating PANoptosis pathway. Environmental pollution (Barking, Essex : 1987). 2024. PMID 38462200. DOI: 10.1016/j.envpol.2024.123713. Access: abstract_metadata. Study: PMID38462200.

23. Zhong Y, Feng Y, Huang Y et al. Polystyrene nanoplastics accelerate atherosclerosis: Unraveling the impact on smooth muscle cells through KIF15-mediated migration. Ecotoxicology and environmental safety. 2024. PMID 39232293. DOI: 10.1016/j.ecoenv.2024.116983. Access: abstract_metadata. Study: APOE-HFD-19W-PS-PLATFORM.

24. Huang H, Hou J, Li M et al. Microplastics in the bloodstream can induce cerebral thrombosis by causing cell obstruction and lead to neurobehavioral abnormalities. Science advances. 2025. PMID 39841831. DOI: 10.1126/sciadv.adr8243. Access: abstract_metadata. Study: PMID39841831.

25. Huang D, Kang H, Liu Z et al. Ferroptosis involved in inhaled polystyrene microplastics leaded myocardial fibrosis through HIF-ROS-SLC7A11/GPX4 Pathway. Journal of environmental sciences (China). 2026. PMID 41005896. DOI: 10.1016/j.jes.2025.04.059. Access: abstract_metadata. Study: PMID41005896.

26. Xu H, Chen S, Wang X et al. Assessing the toxicological effects of exposure to environmental pollutants PET-MPs on vascular diseases: insights from network toxicology, molecular docking, molecular dynamics, and experimental validation. Environmental pollution (Barking, Essex : 1987). 2025. PMID 40939713. DOI: 10.1016/j.envpol.2025.127082. Access: abstract_metadata. Study: PMID40939713.

27. Lin TA, Pan J, Nguyen M et al. Microplastic exposure elicits sex-specific atherosclerosis development in lean low-density lipoprotein receptor-deficient mice. Environment international. 2025. PMID 41275764. DOI: 10.1016/j.envint.2025.109938. Access: abstract_metadata. Study: PMID41275764.

28. Vlacil AK, Bänfer S, Jacob R et al. Polystyrene microplastic particles induce endothelial activation. PloS one. 2021. PMID 34788346. DOI: 10.1371/journal.pone.0260181. Access: abstract_metadata. Study: PMID34788346.

29. D'Onofrio N, Donisi I, Del Vecchio V et al. PCSK9 inhibition ameliorates microplastic-induced endothelial redox imbalance via SIRT6 modulation. Cellular & molecular biology letters. 2025. PMID 41430105. DOI: 10.1186/s11658-025-00838-z. Access: abstract_metadata. Study: PMID41430105.

30. Massie PL, Garcia MA, Gallego D et al. Micro- and nanoplastics are elevated in femoral atherosclerotic plaques compared with undiseased arteries. JVS-vascular science. 2025. PMID 41069702. DOI: 10.1016/j.jvssci.2025.100393. Access: abstract_metadata. Study: PMID41069702.

31. Wei W, Li Y, Lee M et al. Anionic nanoplastic exposure induces endothelial leakiness. Nature communications. 2022. PMID 35963861. DOI: 10.1038/s41467-022-32532-5. Access: abstract_metadata. Study: PMID35963861.

32. Yan J, Pan Y, He J et al. Toxic vascular effects of polystyrene microplastic exposure. The Science of the total environment. 2023. PMID 37734602. DOI: 10.1016/j.scitotenv.2023.167215. Access: abstract_metadata. Study: PMID37734602.

33. Makwana B, Khadke S, Kumar A et al. Marine Microplastic Levels and the Prevalence of Cardiometabolic Diseases in US Coastline Counties. Journal of the American Heart Association. 2025. PMID 40528809. DOI: 10.1161/JAHA.124.039891. Access: abstract_metadata. Study: PMID40528809.

34. Christodoulides A, Hall A, Alves NJ. Exploring microplastic impact on whole blood clotting dynamics utilizing thromboelastography. Frontiers in public health. 2023. PMID 37521965. DOI: 10.3389/fpubh.2023.1215817. Access: abstract_metadata. Study: PMID37521965.

35. Niu H, Li W. Exposure of polystyrene nanoplastics led to ferroptosis on cardiomyocytes. Environmental pollution (Barking, Essex : 1987). 2025. PMID 40532809. DOI: 10.1016/j.envpol.2025.126685. Access: abstract_metadata. Study: PMID40532809.

36. Xie X, Wang K, Shen X et al. Potential mechanisms of aortic medial degeneration promoted by co-exposure to microplastics and lead. Journal of hazardous materials. 2024. PMID 38889468. DOI: 10.1016/j.jhazmat.2024.134854. Access: abstract_metadata. Study: PMID38889468.

37. Cui C, Guo Z, Liu Y et al. Tissue-specific distribution of microplastics in human blood and carotid plaques: A paired sample analysis. Environment international. 2025. PMID 40882421. DOI: 10.1016/j.envint.2025.109743. Access: abstract_metadata. Study: PMID40882421.

38. Long C, Lin M, Wang W et al. RNA-seq and ChIP-seq reveal microplastics induce endothelial-mesenchymal transition via HK2-mediated histone lactylation in pulmonary hypertension. Vascular pharmacology. 2026. PMID 41352427. DOI: 10.1016/j.vph.2025.107571. Access: abstract_metadata. Study: PMID41352427.

39. Wu Y, Chen Y, He R et al. Micronanoplastic exposure due to cardiopulmonary bypass in children: A prospective observational study. Journal of hazardous materials. 2025. PMID 40010211. DOI: 10.1016/j.jhazmat.2025.137732. Access: abstract_metadata. Study: PMID40010211.

40. Yang JZ, Zhang KK, Hsu C et al. Polystyrene nanoplastics induce cardiotoxicity by upregulating HIPK2 and activating the P53 and TGF-β1/Smad3 pathways. Journal of hazardous materials. 2024. PMID 38852254. DOI: 10.1016/j.jhazmat.2024.134823. Access: abstract_metadata. Study: PMID38852254.

41. Leslie HA, van Velzen MJM, Brandsma SH et al. Discovery and quantification of plastic particle pollution in human blood. Environment international. 2022. PMID 35367073. DOI: 10.1016/j.envint.2022.107199. Access: abstract_metadata. Study: PMID35367073.

42. Adler MY, Issoual I, Rückert M et al. Effect of micro- and nanoplastic particles on human macrophages. Journal of hazardous materials. 2024. PMID 38642497. DOI: 10.1016/j.jhazmat.2024.134253. Access: abstract_metadata. Study: PMID38642497.

43. Du B, Li T, He H et al. Analysis of Biodistribution and in vivo Toxicity of Varying Sized Polystyrene Micro and Nanoplastics in Mice. International journal of nanomedicine. 2024. PMID 39081896. DOI: 10.2147/IJN.S466258. Access: abstract_metadata. Study: PMID39081896.

44. Zhang Y, Zhu Y, Wu J et al. Mechanistic Insights into PET-MPs-Aggravated Ischemic Stroke via Integrated Computational-Experimental Approaches. Environmental science & technology. 2026. PMID 42219954. DOI: 10.1021/acs.est.6c00049. Access: abstract_metadata. Study: PMID42219954.

45. Xie J, Ji J, Sun Y et al. Blood-brain barrier damage accelerates the accumulation of micro- and nanoplastics in the human central nervous system. Journal of hazardous materials. 2024. PMID 39366047. DOI: 10.1016/j.jhazmat.2024.136028. Access: abstract_metadata. Study: PMID39366047.

46. Schillemans T, Bergdahl IA, Hanhineva K et al. Associations of PFAS-related plasma metabolites with cholesterol and triglyceride concentrations. Environmental research. 2023. PMID 36243049. DOI: 10.1016/j.envres.2022.114570. Access: abstract_metadata. Study: VIP-PFAS-METABOLOMICS.

47. Blomberg AJ, Shih YH, Messerlian C et al. Early-life associations between per- and polyfluoroalkyl substances and serum lipids in a longitudinal birth cohort. Environmental research. 2021. PMID 34081971. DOI: 10.1016/j.envres.2021.111400. Access: abstract_metadata. Study: PMID34081971.

48. Wang J, Du B, Wu Y et al. Maternal plasma perfluoroalkyl substances concentrations in early pregnancy and cardiovascular development in offspring: A prospective cohort study. Environment international. 2023. PMID 36848830. DOI: 10.1016/j.envint.2023.107748. Access: abstract_metadata. Study: PMID36848830.

49. Stubleski J, Salihovic S, Lind L et al. Changes in serum levels of perfluoroalkyl substances during a 10-year follow-up period in a large population-based cohort. Environment international. 2016. PMID 27542758. DOI: 10.1016/j.envint.2016.08.002. Access: abstract_metadata. Study: PIVUS-LONGITUDINAL.

50. Stubleski J, Salihovic S, Lind PM et al. The effect of drinking water contaminated with perfluoroalkyl substances on a 10-year longitudinal trend of plasma levels in an elderly Uppsala cohort. Environmental research. 2017. PMID 28780137. DOI: 10.1016/j.envres.2017.07.050. Access: abstract_metadata. Study: PIVUS-LONGITUDINAL.

51. Cai D, Fang ZQ, Cui NH et al. Per- and Polyfluoroalkyl Substances, Serum Lipidome, and Clinical Outcomes after Percutaneous Coronary Intervention in Type 2 Diabetic Patients: A Prospective Nested Case-control Study. Journal of atherosclerosis and thrombosis. 2025. PMID 40571603. DOI: 10.5551/jat.65708. Access: abstract_metadata. Study: PMID40571603.

52. Andersson AG, Xu Y, Kärrman A et al. Serum, urinary and fecal concentrations of perfluoroalkyl substances after interventions with cholestyramine/colesevelam and probenecid - cross-over trials in Ronneby, Sweden. Environment international. 2025. PMID 40974835. DOI: 10.1016/j.envint.2025.109794. Access: abstract_metadata. Study: PMID40974835.

53. Møller JJ, Lyngberg AC, Hammer PEC et al. Substantial decrease of PFAS with anion exchange resin treatment - A clinical cross-over trial. Environment international. 2024. PMID 38367552. DOI: 10.1016/j.envint.2024.108497. Access: abstract_metadata. Study: PMID38367552.

54. Gasiorowski R, Forbes MK, Silver G et al. Effect of Plasma and Blood Donations on Levels of Perfluoroalkyl and Polyfluoroalkyl Substances in Firefighters in Australia: A Randomized Clinical Trial. JAMA network open. 2022. PMID 35394514. DOI: 10.1001/jamanetworkopen.2022.6257. Access: full_text_partial. Study: ACTRN12619000204145.

55. Alexander BH, Ryan A, Church TR et al. Mortality and cancer incidence in perfluorooctanesulfonyl fluoride production workers. American journal of industrial medicine. 2024. PMID 38345456. DOI: 10.1002/ajim.23568. Access: abstract_metadata. Study: PMID38345456.

56. Biggeri A, Stoppa G, Facciolo L et al. All-cause, cardiovascular disease and cancer mortality in the population of a large Italian area contaminated by perfluoroalkyl and polyfluoroalkyl substances (1980-2018). Environmental health : a global access science source. 2024. PMID 38627679. DOI: 10.1186/s12940-024-01074-2. Access: abstract_metadata. Study: PMID38627679.

57. Girardi P, Merler E. A mortality study on male subjects exposed to polyfluoroalkyl acids with high internal dose of perfluorooctanoic acid. Environmental research. 2019. PMID 31542491. DOI: 10.1016/j.envres.2019.108743. Access: abstract_metadata. Study: PMID31542491.

58. Donat-Vargas C, Bergdahl IA, Tornevi A et al. Perfluoroalkyl substances and risk of type II diabetes: A prospective nested case-control study. Environment international. 2019. PMID 30622063. DOI: 10.1016/j.envint.2018.12.026. Access: abstract_metadata. Study: VIP-PFAS-DIABETES.

59. Wang T, Li N, Zhao Z et al. Microplastic contamination in kidney transplant donor tissues and its association with early post-transplant blood pressure changes in recipients: A multi-modal analytical study. Journal of hazardous materials. 2025. PMID 40902535. DOI: 10.1016/j.jhazmat.2025.139728. Access: abstract_metadata. Study: PMID40902535.

Source-specific evidence cards

[1] Microplastics and Nanoplastics in Atheromas and Cardiovascular Events.

Shows: Prospective carotid-surgery cohort follows 257 of 304 enrolled for about 34 months; plaque polymers associate with a composite of myocardial infarction, stroke or all-cause death.

Does not show: The reported 4.53 hazard ratio is observational and the composite includes all-cause death; diseased-plaque selection, residual confounding and contamination do not isolate particle causation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:METHODS:paragraph0, 0:METHODS:paragraph1, 0:METHODS:paragraph2, 0:METHODS:paragraph3, 0:METHODS:paragraph5, 1:RESULTS:paragraph0, 1:RESULTS:paragraph1, 1:RESULTS:paragraph2, 1:RESULTS:paragraph5, 1:RESULTS:paragraph6, 2:DISCUSSION:paragraph3, 2:DISCUSSION:paragraph4. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[2] Circulating Microplastics in Acute Ischemic Stroke: Feasibility, Variability, and Exploratory Comparisons with Healthy Individuals.

Shows: Contamination-controlled pilot blood analysis finds particles in 20 stroke patients and 15 controls; the within-study particle-count difference is not significant.

Does not show: An exploratory pooled external healthy reference produces a positive comparison with heterogeneous assays; it cannot establish disease-specific elevation or causation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[3] Isolation and characterization of microplastics from human blood samples by confocal RAMAN microscopy.

Shows: Raman blood-particle workflow uses negative and positive controls plus clinical-material reference spectra to trace contamination and chemically identify polymers.

Does not show: An analytical detection protocol does not quantify prospective cardiovascular risk or particle-specific clinical harm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[4] A new screening framework to support the identification of exogenous particles and suspect microplastics in situ in pathological tissue samples.

Shows: Ileal biopsy screening identifies many apparent subepithelial particles as procedural contaminants; limited remaining observations illustrate translocation and chemical cross-checks.

Does not show: Suspect particles include starch and a viscose fibre; the framework is not cardiovascular tissue evidence or causal injury.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[5] Label-Free Identification and Imaging of Microplastic and Nanoplastic Biouptake Using Optical Photothermal Infrared Microspectroscopy.

Shows: Label-free O-PTIR and microtomy localize and identify plastics in exposed aquatic and terrestrial experimental organisms.

Does not show: Method validation in Daphnia, flies and worms does not establish human cardiovascular accumulation or clinical effects.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[6] Cross-platform detection of microplastics in human biological tissues: Comparing spectroscopic and chromatographic approaches.

Shows: Paired human endometrial and urine samples demonstrate complementary Raman particle morphology and pyrolysis polymer sensitivity, with discordant polymer detection.

Does not show: Different assay sensitivities and nonvascular tissue prevent treating bulk mass, particle number and clinical cardiovascular burden as interchangeable.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[7] Hydrogel Transformation Reveals a Conventionally Inaccessible Sub-Micrometer Microplastic Fraction in Intact Human Tissues.

Shows: Hydrogel tissue-clearing fluorescence workflow with spiked controls and artifact benchmarks resolves a submicrometer fraction in human placenta that bulk-mass methods miss.

Does not show: Nile Red-based identity still requires chemical corroboration; placental analytic validation does not prove vascular toxicity or clinical risk.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[8] Label-free non-destructive spectroscopic detection of mixed microplastic uptake and differential effects on intestinal epithelial cells.

Shows: O-PTIR identifies mixed-polymer uptake and metabolic spectral changes in intestinal cells after 24-hour exposure at 25-100 micrograms per mL.

Does not show: Cell stress at the administered concentration does not establish realistic human vascular exposure, specific mediation or clinical disease.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[9] Suspected Microplastic-Like Particles Recovered From Paired Human Small Intestine and Large Intestine Specimens: An Exploratory Post-mortem Study.

Shows: Post-mortem intestinal screening in 55 adults identifies suspected plastic-like fluorescent particles and exploratory inflammation co-occurrence.

Does not show: The assay is not polymer-specific and unadjusted heterogeneous pathology does not establish true particle identity or causal inflammation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[10] Long-Chain Acyl Carnitines Aggravate Polystyrene Nanoplastics-Induced Atherosclerosis by Upregulating MARCO.

Shows: Nineteen-week gavage of 50-nm polystyrene at 2.5-250 mg per kg with high-fat diet aggravates ApoE-knockout arterial stiffness and plaque formation with MARCO and acylcarnitine changes.

Does not show: High doses, susceptible genotype and diet are experimental conditions, not demonstrated real-world human exposure or isolated human mediation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[11] Microplastics in human blood: Polymer types, concentrations and characterisation using μFTIR.

Shows: Chemical FTIR blood analysis in 20 healthy volunteers identifies multiple polymers and reports procedural blanks and particle size distributions.

Does not show: Detection and hypotheses about thrombosis do not establish prospective cardiovascular risk; mass and number thresholds differ.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[12] Nanoplastics causes heart aging/myocardial cell senescence through the Ca2+/mtDNA/cGAS-STING signaling cascade.

Shows: Nanoplastic exposure produces cardiac senescence and oxidative-stress mitochondrial-DNA and cGAS-STING changes in cell and animal models.

Does not show: Senescence markers and pathway activation do not demonstrate clinical cardiac events or pathway necessity at human exposures.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[13] Detection of Various Microplastics in Patients Undergoing Cardiac Surgery.

Shows: Heart-associated tissue and paired blood sampling in 15 cardiac-surgery patients identifies polymers with postoperative changes in type and size distributions.

Does not show: Surgical introduction and diseased-tissue selection complicate exposure inference; detection is not proof that particles caused the indication for surgery.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[14] Microplastics in three types of human arteries detected by pyrolysis-gas chromatography/mass spectrometry (Py-GC/MS).

Shows: Pyrolysis analysis finds polymer mass in 17 arterial samples, with higher concentrations in plaque-bearing coronary and carotid arteries than plaque-free aortas.

Does not show: Vascular site and plaque status differ together; bulk polymer detection and cross-sectional comparison do not isolate particle-induced atherosclerosis.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[15] Low-dose of polystyrene microplastics induce cardiotoxicity in mice and human-originated cardiac organoids.

Shows: Administered polystyrene induces oxidative injury and hypertrophic changes in mice and human-derived cardiac organoids, including an asserted low internal-exposure concentration.

Does not show: Organoid exposure equivalence is not validated human pharmacokinetics; cardiac markers and wall thickness are not major adverse human clinical events.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[16] Long-term polystyrene nanoplastic exposure disrupt hepatic lipid metabolism and cause atherosclerosis in ApoE-/- mice.

Shows: Three-month polystyrene exposure produces aortic plaques in ApoE-knockout mice alongside hepatic lipid disturbances; macrophage experiments show ox-LDL coexposure effects.

Does not show: A susceptible strain and lipid context define experimental causality; dose translation and particle-specific human clinical mediation remain untested.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[17] Microplastics are associated with elevated atherosclerotic risk and increased vascular complexity in acute coronary syndrome patients.

Shows: Cross-sectional chest-pain cohort of 101 participants associates blood polymer levels with ACS severity, vascular complexity and immune-inflammatory measures.

Does not show: Disease and exposure are measured together; reverse causation, procedural contamination and confounding preclude clinical causal inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[18] Unveiling the Heart's Hidden Enemy: Dynamic Insights into Polystyrene Nanoplastic-Induced Cardiotoxicity Based on Cardiac Organoid-on-a-Chip.

Shows: Cardiac organoid-on-chip exposure reveals time- and pathological-state-dependent polystyrene toxicity; low-dose effects are stronger in infarction-like models than healthy models.

Does not show: A constructed infarction state and administered particles do not establish real-world human MACE or define clinical susceptibility prospectively.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[19] Microplastics and nanoplastics increase major adverse cardiac events in patients with myocardial infarction.

Shows: Prospective post-MI cohort follows 110 of 142 patients for about 31.5 months; coronary PVC concentration associates with MACE and inflammatory markers, with an additional 21-patient thrombus sample.

Does not show: Observational odds estimates are not randomized risks; the abstract's fold-increase wording differs from its listed OR, so numeric causal-risk conversion is withheld.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[20] Multimodal detection and analysis of microplastics in human thrombi from multiple anatomically distinct sites.

Shows: Multimodal chemical and microscopic testing finds polymers in 24 of 30 thrombi across stroke, MI and DVT, with burden-severity associations.

Does not show: Thrombus sampling after clinical disease cannot establish temporal particle causation; mass, morphology and site differ.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[21] Co-exposure to polystyrene nanoplastics and F-53B induces vascular endothelial cell pyroptosis through the NF-κB/NLRP3 pathway.

Shows: Individual and combined polystyrene and F-53B exposure produce mouse vascular injury and endothelial inflammatory pathway changes.

Does not show: PFAS analogue and particle coexposure are distinct; combined toxicity cannot identify the source of real-world human cardiovascular events.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC5.

[22] Polystyrene nanoplastics and cadmium co-exposure aggravated cardiomyocyte damage in mice by regulating PANoptosis pathway.

Shows: Thirty-five-day polystyrene and cadmium exposure in male mice produces cardiac injury and death-pathway changes, greater with combined exposure.

Does not show: Claimed environmental relevance does not establish human internal dose; cadmium, sickness and pathway markers limit particle-specific clinical attribution.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[23] Polystyrene nanoplastics accelerate atherosclerosis: Unraveling the impact on smooth muscle cells through KIF15-mediated migration.

Shows: Nineteen-week polystyrene exposure in ApoE-knockout high-fat-fed mice accompanies plaque development and smooth-muscle migration changes with Kif15 knockdown experiments.

Does not show: Shared dose, duration and experimental platform with related MARCO work require conservative independence grouping; cell migration is not an isolated human clinical mediator.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[24] Microplastics in the bloodstream can induce cerebral thrombosis by causing cell obstruction and lead to neurobehavioral abnormalities.

Shows: Mouse in-vivo imaging connects circulating particle-phagocyte aggregates with cortical microvascular obstruction, reduced flow and neurobehavioral abnormalities.

Does not show: Administered bloodstream exposure and species-specific capillary conditions do not quantify typical human oral exposure or clinical stroke incidence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[25] Ferroptosis involved in inhaled polystyrene microplastics leaded myocardial fibrosis through HIF-ROS-SLC7A11/GPX4 Pathway.

Shows: Inhaled 5-micrometer polystyrene impaired mouse cardiac function and induced fibrosis; ferroptosis/HIF/oxidative-stress inhibitors improved selected cellular injury measures.

Does not show: Inhalation-model doses, cell inhibitor effects and fibrosis do not establish human MACE at measured real-world internal exposures.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[26] Assessing the toxicological effects of exposure to environmental pollutants PET-MPs on vascular diseases: insights from network toxicology, molecular docking, molecular dynamics, and experimental validation.

Shows: PET network-toxicology predictions were followed by VSMC experiments showing oxidative stress, mitochondrial changes and apoptosis.

Does not show: Docking/simulations are not causal items; cell validation without whole-organism clinical events cannot prove particle-specific vascular mediation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[27] Microplastic exposure elicits sex-specific atherosclerosis development in lean low-density lipoprotein receptor-deficient mice.

Shows: Daily 10 mg/kg gavage for nine weeks increased aortic-root lesions in lean male LDLR-deficient mice but not females, without lipid or adiposity change.

Does not show: The sex boundary and sensitized genotype are experimental; the brachiocephalic estimate was nonsignificant, and asserted environmental relevance is not validated human dose equivalence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[28] Polystyrene microplastic particles induce endothelial activation.

Shows: Carboxylated polystyrene induced endothelial adhesion/leukocyte activation in cells and aortic cytokine/adhesion changes in exposed mice.

Does not show: Inflammatory markers and particle clearance do not establish human clinical events or pathway-specific necessity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[29] PCSK9 inhibition ameliorates microplastic-induced endothelial redox imbalance via SIRT6 modulation.

Shows: PE/PVC-exposed endothelial cells showed inflammatory/redox injury; evolocumab improved selected measures and SIRT6 silencing removed some benefit.

Does not show: Concentrations of 30-70 micrograms/mL, transient cell silencing and pleiotropic drug rescue cannot establish preventive clinical treatment or human MACE mediation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[30] Micro- and nanoplastics are elevated in femoral atherosclerotic plaques compared with undiseased arteries.

Shows: Pyrolysis analysis found much higher polymer mass in ten femoral plaques from eight patients than thirty decedent carotid controls.

Does not show: Vessel site, tissue type, clinical disease and collection circumstances differ; bulk mass and small cross-sectional comparisons do not prove particle-caused disease.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[31] Anionic nanoplastic exposure induces endothelial leakiness.

Shows: Anionic polystyrene/PMMA disrupted endothelial cadherin junctions in dose-dependent cell, ex-vivo and animal assays, without linkage to several cytotoxic stress routes.

Does not show: Biophysical leakiness offers an alternative to universal inflammation-first explanations but does not demonstrate human exposure-specific clinical events.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[32] Toxic vascular effects of polystyrene microplastic exposure.

Shows: Fecal particles correlated with aortic calcification in 47 patients; polystyrene caused mild rat calcification and worsened vitamin-D/nicotine-induced disease.

Does not show: Fecal exposure and cross-sectional calcification are not human MACE; experimental coexposure and gut effects do not isolate realistic human causation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[33] Marine Microplastic Levels and the Prevalence of Cardiometabolic Diseases in US Coastline Counties.

Shows: County-level marine particle categories associated with higher adjusted prevalence of diabetes, coronary disease and stroke near US coastlines.

Does not show: Ecological water categories are not individual internal exposure; spatial socioeconomic confounding and prevalence cannot establish person-level causation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[34] Exploring microplastic impact on whole blood clotting dynamics utilizing thromboelastography.

Shows: Whole-blood thromboelastography found size/concentration-dependent clot activation with carboxylated polystyrene, while unmodified particles often had little effect.

Does not show: Surface chemistry and ex-vivo clotting differ from spontaneous clinical thrombosis at ordinary exposures; assay activation is not human MACE.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[35] Exposure of polystyrene nanoplastics led to ferroptosis on cardiomyocytes.

Shows: Polystyrene-exposed primary rat cardiomyocytes developed iron/oxidative injury and reduced viability, with deferoxamine restoring selected cellular outcomes.

Does not show: Cell rescue supports a pathway in that model, not organismal clinical cardiovascular injury or particle-specific human dose relevance.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[36] Potential mechanisms of aortic medial degeneration promoted by co-exposure to microplastics and lead.

Shows: Particles and lead co-occurred in aortic disease samples; combined mouse exposure damaged aortic structure and cell rescue reduced selected oxidative/death signals.

Does not show: Metal coexposure, cell pharmacology and vascular injury cannot partition particle versus lead contribution to human cardiovascular events.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[37] Tissue-specific distribution of microplastics in human blood and carotid plaques: A paired sample analysis.

Shows: Paired blood and carotid plaque polymer measurements in twenty surgery patients showed tissue-specific distributions and modest total-burden correlation.

Does not show: Diseased-tissue selection and polymer-mass measurements do not establish particle number, baseline general-population exposure or causal clinical harm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[38] RNA-seq and ChIP-seq reveal microplastics induce endothelial-mesenchymal transition via HK2-mediated histone lactylation in pulmonary hypertension.

Shows: Particles aggravated monocrotaline rat pulmonary hypertension; HK2 knockdown counteracted endothelial transition and lactylation changes in cells.

Does not show: Pre-existing induced disease, airway administration and cell mediator perturbation do not prove isolated human MACE causation or in-vivo mediator necessity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[39] Micronanoplastic exposure due to cardiopulmonary bypass in children: A prospective observational study.

Shows: Paired samples from 22 children showed increased polymer mass and particle counts after cardiopulmonary bypass, with procedure-time and leukocyte associations.

Does not show: Surgery provides a credible exposure source but concurrent injury/inflammation and no unexposed control prevent attribution of clinical harm to particles.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[40] Polystyrene nanoplastics induce cardiotoxicity by upregulating HIPK2 and activating the P53 and TGF-β1/Smad3 pathways.

Shows: Six-week oral polystyrene caused mouse apoptosis, fibrosis and dysfunction and worsened isoprenaline injury; HIPK2 inhibition reduced selected cardiotoxicity.

Does not show: Mouse dose and pathological-state manipulation do not establish human environmental internal exposure or major-event causation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[41] Discovery and quantification of plastic particle pollution in human blood.

Shows: Validated pyrolysis workflow quantified several polymers in blood from 22 healthy volunteers, with polypropylene below quantification.

Does not show: Polymer mass above assay thresholds is not particle-resolved cardiovascular risk, and detection alone cannot establish toxicity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[42] Effect of micro- and nanoplastic particles on human macrophages.

Shows: Primary human and THP1-derived macrophages took up polystyrene beads with size/concentration-dependent metabolic activity, necrosis and ROS.

Does not show: Cell uptake and stress cannot prove upstream clinical vascular inflammation or physiological exposure equivalence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[43] Analysis of Biodistribution and in vivo Toxicity of Varying Sized Polystyrene Micro and Nanoplastics in Mice.

Shows: Twenty-eight-day oral polystyrene showed size/dose-dependent distribution and biochemical changes in mice, without abnormal behavior or weight change; low-dose organs lacked severe histology.

Does not show: Fluorescence, proxy changes and mild/null phenotypes do not establish human cardiac events; negative observations remain part of the record.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[44] Mechanistic Insights into PET-MPs-Aggravated Ischemic Stroke via Integrated Computational-Experimental Approaches.

Shows: PET exposure worsened infarction and neurologic deficits in experimentally occluded mice with microglial/oxidative changes.

Does not show: Aggravation after induced ischemia is not increased spontaneous human stroke incidence; computational target predictions are not independent causal evidence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[45] Blood-brain barrier damage accelerates the accumulation of micro- and nanoplastics in the human central nervous system.

Shows: Twenty-eight CSF samples associated some polymers with barrier-damage markers but did not associate particle concentrations with IL6 or IL8.

Does not show: Infection-related barrier injury provides a reverse-direction alternative; small cross-sectional CSF data do not disprove all vascular inflammation mechanisms.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[46] Associations of PFAS-related plasma metabolites with cholesterol and triglyceride concentrations.

Shows: PFAS-related metabolite patterns in 187 longitudinally sampled controls associated inversely with triglycerides but not cholesterol.

Does not show: Metabolomic correlations and an inferred pathway are not clinical cardiovascular events or chemical-specific causal instruments.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[47] Early-life associations between per- and polyfluoroalkyl substances and serum lipids in a longitudinal birth cohort.

Shows: Repeated PFAS/lipid measurements in 490 children associated later childhood exposures with several lipid fractions and sex-dependent patterns.

Does not show: Lipids are surrogate risk measures; repeated observational sampling does not prove adult major-event causation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[48] Maternal plasma perfluoroalkyl substances concentrations in early pregnancy and cardiovascular development in offspring: A prospective cohort study.

Shows: Maternal PFAS measured early in pregnancy associated with offspring cardiac-wall and vascular morphology at age four in 957 children.

Does not show: Mixture models and developmental morphology are not adult MACE; thinner carotid thickness is not automatically an atherosclerotic adverse-event mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[49] Changes in serum levels of perfluoroalkyl substances during a 10-year follow-up period in a large population-based cohort.

Shows: Repeated PIVUS sampling documented chemical-specific increases and decreases in serum PFAS across ages 70-80, including a local PFHxS contamination signal.

Does not show: Exposure kinetics are not clinical risk or removal benefit; repeated reports from this cohort do not create independent investigations.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5, SC6.

[50] The effect of drinking water contaminated with perfluoroalkyl substances on a 10-year longitudinal trend of plasma levels in an elderly Uppsala cohort.

Shows: PIVUS residents receiving more contaminated water showed increasing serum PFHxS, unlike several other chemicals.

Does not show: Water-source contrast demonstrates an exposure pathway, not a chemical-specific cardiovascular-event effect or improved health after removal.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5, SC6.

[51] Per- and Polyfluoroalkyl Substances, Serum Lipidome, and Clinical Outcomes after Percutaneous Coronary Intervention in Type 2 Diabetic Patients: A Prospective Nested Case-control Study.

Shows: A prospective diabetes/PCI nested case-control analysis associated baseline PFAS mixtures and lipidomic patterns with two-year MACCE odds.

Does not show: Statistical lipid mediation, selected coronary disease and residual confounding do not establish chemical causation; ambiguous indexed case-pair wording is not expanded into a verified case count.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[52] Serum, urinary and fecal concentrations of perfluoroalkyl substances after interventions with cholestyramine/colesevelam and probenecid - cross-over trials in Ronneby, Sweden.

Shows: Ten-person crossover interventions increased fecal PFOS excretion with cholestyramine and lowered serum PFOS with colesevelam versus observation; probenecid did not improve urinary PFOS.

Does not show: Chemical elimination and serum decline are not clinical health outcomes; very small crossover data cannot validate retail detox or a benefit-harm profile.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC6, SC4.

[53] Substantial decrease of PFAS with anion exchange resin treatment - A clinical cross-over trial.

Shows: Randomized-sequence open-label crossover in 45 highly exposed adults reduced serum PFOS by about 60% with anion-exchange resin versus observation.

Does not show: Primary endpoint was serum concentration, not clinical benefit; absence of serious events in a small short study is not proof of broad safety or efficacy of detox products.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC6, SC4.

[54] Effect of Plasma and Blood Donations on Levels of Perfluoroalkyl and Polyfluoroalkyl Substances in Firefighters in Australia: A Randomized Clinical Trial.

Shows: Randomized 285-firefighter trial reduced selected serum PFAS; body Results distinguish within-group from between-group chemical contrasts and report no improvement in several laboratory-health panels.

Does not show: Burden reduction is not clinical-event efficacy or demonstrated particle clearance; blood donation lowered hemoglobin and plasma donation had more adverse events. Donor eligibility and sex distribution restrict scope.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph3, 1:Methods:paragraph5, 1:Methods:paragraph6, 1:Methods:paragraph7, 2:Results:paragraph0, 2:Results:paragraph1, 2:Results:paragraph2, 2:Results:paragraph3, 2:Results:paragraph4, 2:Results:paragraph5, 2:Results:paragraph6, 2:Results:paragraph7, 2:Results:paragraph8, 2:Results:paragraph9, 2:Results:paragraph11, 2:Results:paragraph13, 2:Results:paragraph14, 2:Results:paragraph15. No complete-paper or supplement audit claimed. none_found. Subclaims: SC6, SC4.

[55] Mortality and cancer incidence in perfluorooctanesulfonyl fluoride production workers.

Shows: Occupational PFOS-equivalent analysis found excess cerebrovascular mortality in the highest exposure quartile relative to national expectations, with many imprecise/null within-cohort estimates.

Does not show: Healthy-worker effects, exposure reconstruction and reference comparisons limit causal inference; chemical mixtures are not plastic particles.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[56] All-cause, cardiovascular disease and cancer mortality in the population of a large Italian area contaminated by perfluoroalkyl and polyfluoroalkyl substances (1980-2018).

Shows: Residence-defined PFAS-contaminated Italian municipalities had higher all-cause and selected cardiovascular mortality than regional expectations.

Does not show: Geographic exposure, assumed contamination onset and regional confounding do not isolate chemical-specific human causal events.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[57] A mortality study on male subjects exposed to polyfluoroalkyl acids with high internal dose of perfluorooctanoic acid.

Shows: A small highly exposed male factory cohort showed elevated mortality for selected hepatic, diabetes and cancer outcomes compared with reference groups.

Does not show: The abstract does not establish a specific cardiovascular-event effect; coexposures and limited confounder control prevent broad PFAS-MACE extrapolation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[58] Perfluoroalkyl substances and risk of type II diabetes: A prospective nested case-control study.

Shows: A prospective nested case-control study found mostly nonsignificant inverse PFAS-diabetes associations and lower insulin resistance in controls.

Does not show: A noncardiovascular outcome is a boundary against uniform metabolic-harm claims, not proof that PFAS cannot cause cardiovascular harm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[59] Microplastic contamination in kidney transplant donor tissues and its association with early post-transplant blood pressure changes in recipients: A multi-modal analytical study.

Shows: Multimodal polymer measurements in 28 donor tissues found mostly nonsignificant exploratory associations with recipient blood pressure 15 days after transplantation.

Does not show: Short postoperative proxies and many tissue/polymer comparisons cannot establish particle-caused MACE; unclear indexed regression/FDR wording is not interpreted as a causal numerical result.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• CONSENSUS_CROSSCHECK.html
• CONSENSUS_CROSSCHECK.md
• RESEARCH_TIMELINE.html
• RESEARCH_TIMELINE.md
• SHA256.txt
• adversarial-findings.json
• codex-correction-provenance.json
• consensus-validation.json
• edition-approval-audit.json
• microplastics-cardiovascular.review.md
• microplastics-cardiovascular.scorecard.json
• reader-summary.json
• research-timeline.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt
• video-insert.md
• web-page.md

Sources: 59 · load-bearing claims: 66 · verified: 66 · unverified: 0 · contradicted: 0 · schema 5.3